Merck speeds up drug-submission plans for Hep C, lung cancer: WSJ

January 12, 2015 6:51 AM

14 0

(Reuters) - Merck & Co has put on fast track its plans to submit new drugs for hepatitis C and lung cancer for regulatory approval, in an attempt to close the gap with competitors in two lucrative segments, the Wall Street Journal reported.

The drugmaker will file an application midyear for U.S. regulatory approval to expand the use of its new cancer immunotherapy Keytruda to include the treatment of non-small-cell lung cancer, the most common form of the deadly disease, the Journal reported. (

Read more

To category page